Chimeric antibody against tumor associated antigens and its use in diagnosing tumors

US7662383B2 · kind B2 · utility

Assignee

• Aventis Pharma Deutschland GmbH · DE

Inventors

• Klaus Bosslet · Marburg, DE
• Gerhard Seemann · Lahntal, DE
• Hans-Harald Sedlacek · Marburg, DE
• Bernhard Auerbach · Marburg, DE

Key dates

• Filing date: Feb 7, 2008
• Grant date: Feb 16, 2010
• Expiry date: Jul 30, 2028

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to murine monoclonal antibodies (MAbs), A, B, C and D, which are directed against tumor-associated antigens. The nearly complete nucleotide sequences of the V genes of these MAbs are described, so that the relevant variable domains can be put together to give chimeric MAbs, or “humanized” MAbs are obtained by inserting the hypervariable regions (complementarity determining regions=CDR) into a human MAb framework. Antibody constructs of this type can be employed in human therapy and in vivo diagnosis without the disadvantages observed with murine MAbs.